Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. In countries or local communities where COVID-19 infection is widely spread, MM patients should have a PCR test of nasopharyngeal swab for SARS-CoV-2 before hospital admission, starting a new treatment line, cell apheresis or ASCT in order to avoid ward or community spread and infections. Oral agent-based regimens should be considered, especially for the elderly and frail patients with standard risk disease, whereas de-intensified regimens for dexamethasone, bortezomib, carfilzomib and daratumumab should be used based on patient risk and response. Treatment initiation should not be postponed for patients with end organ damage, myeloma emergencies and aggressive relapses. Autologous (and especially allogeneic) transplantation should be delayed and extended induction should be administered, especially in standard risk patients and those with adequate MM response to induction. Watchful waiting should be considered for standard risk relapsed patients with low tumor burden, and slow biochemical relapses. The conduction of clinical trials should continue with appropriate adaptations to the current circumstances. Patients with MM and symptomatic COVID-19 disease should interrupt anti-myeloma treatment until recovery. For patients with positive PCR test for SARS-CoV-2, but with no symptoms for COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. The need for surveillance for drug interactions due to polypharmacy is highlighted. The participation in international COVID-19 cancer registries is greatly encouraged.

Cancer Research Unit University Hospital of Salamanca Instituto de Investigación Biomédica de Salamanca Salamanca Spain

Clínica Universidad de Navarra Centro de Investigación Médica Aplicada Instituto de Investigación Sanitaria de Navarra Centro de Investigación Biomédica en Red de Cáncer Pamplona Spain

Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece

Department of Hemato Oncology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Hematology Cancer Center Amsterdam Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands

Department of Hematology University Hospital Hotel Dieu Nantes France

Department of Internal Medicine 2 University Hospital of Würzburg Würzburg Germany

Division of Hematology University of Turin Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Turin Italy

Faculty of Freiburg Hematology and Oncology Department Interdisciplinary Cancer Center University of Freiburg Freiburg Germany

Genomics of Myeloma Laboratory L'Institut Universitaire du Cancer Oncopole Toulouse France

Institute of Cancer Molecular and Cellular Biology Salamanca Spain

Leeds Cancer Centre Leeds Teaching Hospitals National Health Service Trust and University of Leeds Leeds UK

Wilhelminen Cancer Research Institute c o Department of Medical Oncology Hematology and Palliative Care Wilhelminenspital Wien Austria

Zobrazit více v PubMed

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. 10.1001/jama.2020.2648. [Epub ahead of print]. PubMed

Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc Natl Acad Sci USA. 2020;117:9696–8. doi: 10.1073/pnas.2004911117. PubMed DOI PMC

Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020. pii: S0012-3692(20)30710-8. 10.1016/j.chest.2020.04.010. [Epub ahead of print]. PubMed PMC

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020. 10.1158/2159-8290.CD-20-0422. [Epub ahead of print]. PubMed PMC

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. pii: S0923–7534(20)36383–3. 10.1016/j.annonc.2020.03.296. [Epub ahead of print]. PubMed PMC

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7. doi: 10.1016/S1470-2045(20)30096-6. PubMed DOI PMC

Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–9. doi: 10.1200/GO.20.00097. PubMed DOI PMC

Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol. 2020. pii: S0923-7534(20)39293-0. 10.1016/j.annonc.2020.04.002. [Epub ahead of print]. PubMed PMC

Sorrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102:182–90. doi: 10.1111/ejh.13190. PubMed DOI

Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28:75–86. doi: 10.1016/j.blre.2014.01.004. PubMed DOI

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13. doi: 10.3324/haematol.2014.107714. PubMed DOI PMC

Holmstrom MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90:E73–74. doi: 10.1002/ajh.23932. PubMed DOI

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis. Crit Rev Oncol Hematol. 2018;130:27–35. doi: 10.1016/j.critrevonc.2018.07.003. PubMed DOI

Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol. 2018;97:925–44. doi: 10.1007/s00277-018-3284-y. PubMed DOI

Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145–50. doi: 10.4049/jimmunol.0901596. PubMed DOI

Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290–4300. doi: 10.1158/1078-0432.CCR-16-3192. PubMed DOI PMC

Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE. 2019;14:e0211927. doi: 10.1371/journal.pone.0211927. PubMed DOI PMC

Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84–94. doi: 10.1016/j.blre.2019.01.001. PubMed DOI

Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760–72. doi: 10.1016/S1470-2045(19)30506-6. PubMed DOI PMC

Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Spat-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105:1183–1188. doi: 10.3324/haematol.2019.242958. PubMed DOI PMC

Bringhen S, Milan A, Ferri C, Wasch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy—incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) Haematologica. 2018;103:1422–32. doi: 10.3324/haematol.2018.191288. PubMed DOI PMC

Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–66. doi: 10.3324/haematol.2014.117176. PubMed DOI PMC

Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307–10. doi: 10.1182/bloodadvances.2020001907. PubMed DOI PMC

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 Patients Infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020. 10.1001/jama.2020.5394. [Epub ahead of print], https://www.ncbi.nlm.nih.gov/pubmed/?term=32250385. PubMed PMC

Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020. 10.1056/NEJMc2010419. [Epub ahead of print], https://www.ncbi.nlm.nih.gov/pubmed/?term=32302078. PubMed PMC

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020. 10.1002/ajh.25829. [Epub ahead of print]. PubMed PMC

Rajkumar S, Cavo M, Mikhail J, Mateos M, Jackson G, Moreau P, et al. COVID-19 and Multiple myeloma: frequently asked questions (Version 1.0; last reviewed April 7, 2020). https://www.hematology.org/covid-19/covid-19-and-multiple-myeloma Accessed 19 April 2020.

European Society of Medical Oncology. ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-covid-19-era Accessed 19 April 2020.

von Lilienfeld-Toal M, Greinix H, Hirsch H, Na I-K, Sandherr M, Schanz U, et al. Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen. Onkopedia. Version vom 15. https://www.onkopedia.com/de/onkopedia/guidelines/coronavirus-infektion-covid-19-bei-patienten-mit-blut-und-krebserkrankungen/@@guideline/html/index.html?chapter=6.2.48#ID0EASBG Accessed 19 April 2020.

UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak (25 March 2020). Accessed 19 April 2020.

Chemotherapy Clinical Reference Group UK. Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England (20 April 2020). Accessed 20 April 2020.

HOVON/Dutch Federation of Hematology. Recommendations for patients with multiple myeloma during the COVID-19 epidemic [dutch]. http://www.hematology.nl. Accessed 19 April 20.

International Myeloma Society. International Myeloma Society Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. https://cms.cws.net/content/beta.myelomasociety.org/files/IMS%20recommendations%20for%20Physicians%20Final.pdf Accessed 19 April 2020.

Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol. 2020;31:553–555. doi: 10.1016/j.annonc.2020.03.286. PubMed DOI PMC

Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020: 1–4. 10.6004/jnccn.2020.7560. [Epub ahead of print]. PubMed

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol. 2020;189:241–3. doi: 10.1111/bjh.16620. PubMed DOI PMC

von Lilienfeld-Toal M, Vehreschild J, Cornely O, Pagano L, Compagno F, EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020; in press. 10.1038/s41375-020-0832-y. [Epub ahead of print]. PubMed PMC

Mian H, Grant SJ, Engelhardt M, Pawlyn C, Bringhen S, Zweegman S, et al. Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. J Geriatri Oncol. 2020. pii: S1879-4068(20)30190-9. 10.1016/j.jgo.2020.04.008. [Epub ahead of print]. PubMed PMC

Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32:2495–518. doi: 10.1038/s41375-018-0120-2. PubMed DOI PMC

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347–57. doi: 10.1200/JCO.2012.47.7901. PubMed DOI PMC

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) Blood Cancer J. 2019;9:27. doi: 10.1038/s41408-019-0187-7. PubMed DOI PMC

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548. doi: 10.1016/S1470-2045(14)70442-5. PubMed DOI

Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: Role of autologous transplantation. Cancer Treat Rev. 2020;82:101929. doi: 10.1016/j.ctrv.2019.101929. PubMed DOI

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38. doi: 10.1016/S0140-6736(19)31240-1. PubMed DOI

Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185:492–502. doi: 10.1111/bjh.15806. PubMed DOI PMC

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67. doi: 10.1002/ajh.25791. PubMed DOI

Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337–45. doi: 10.1182/blood.2019000241. PubMed DOI PMC

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. doi: 10.1056/NEJMoa1611750. PubMed DOI PMC

Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–85. doi: 10.1038/leu.2014.60. PubMed DOI PMC

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–107. doi: 10.1016/S0140-6736(19)32556-5. PubMed DOI

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22. doi: 10.1056/NEJMoa1805762. PubMed DOI

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727–38. doi: 10.1056/NEJMoa1903455. PubMed DOI

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21. doi: 10.1016/S1470-2045(19)30788-0. PubMed DOI

Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–47. doi: 10.1056/NEJMoa1300439. PubMed DOI

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126–37. doi: 10.1200/JCO.19.01740. PubMed DOI PMC

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. doi: 10.1038/s41408-018-0077-4. PubMed DOI PMC

Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel). 2020;12. pii: E191. https://www.ncbi.nlm.nih.gov/pubmed/?term=31940972. PubMed PMC

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–9. doi: 10.1182/blood-2011-03-344333. PubMed DOI

Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, et al. Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study. Clin Cancer Res. 2016;22:1378–84. doi: 10.1158/1078-0432.CCR-15-1864. PubMed DOI

Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534–9. doi: 10.1182/blood-2018-11-852459. PubMed DOI

de Paula BHR, Araujo I, Bandeira L, Barreto N, Doherty GJ. Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. Lancet Oncol. 2020;21:624–7. doi: 10.1016/S1470-2045(20)30226-6. PubMed DOI PMC

Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370–80. doi: 10.1016/S2352-3026(20)30070-3. PubMed DOI

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes D, Molinaro M, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions. Ther Drug Monit. 2020. 10.1097/FTD.0000000000000761. [Epub ahead of print]. PubMed PMC

Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) treatment. J Am Coll Cardiol. 2020. pii: S0735-1097(20)34918-4. 10.1016/j.jacc.2020.04.016. [Epub ahead of print]. PubMed PMC

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma